ABSTRACT Objective The optimal approach to the treatment of colorectal carcinoma and synchronous liver metastases remains controversial. The objective of this review was to analyze the outcomes of adopting the liver-first approach for the treatment of patients with colorectal cancer with synchronous hepatic metastases who initially underwent systemic chemotherapy and/or resection of the metastatic lesions and primary colorectal carcinoma. Methods This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The MEDLINE, EMBASE, […]

Highlights Radiofrequency ablation and percutaneous ethanol injection are neoadjuvant hepatocellular carcinoma treatment methods. Radiofrequency ablation achieves a higher complete response rate (96.3% versus 60.0%, p=0.001). Total cost analyses showed radiofrequency ablation as a more expensive method (p<0.001). The incremental cost-effectiveness ratio was US$ -2674.59 with an advantage for radiofrequency ablation. Incremental effectiveness (34.2%) was in favor of radiofrequency ablation versus percutaneous ethanol injection. ABSTRACT Objective: This study assessed the cost-effectiveness of radiofrequency ablation compared with percutaneous ethanol injection in patients […]

Highlights Once complete hepatocellular carcinoma necrosis is achieved, the diameter of the hepatocellular carcinoma decreases significantly, regardless of its initial size. Hepatocellular carcinoma >3cm showed greater reduction and longer time to recurrence. Hepatocellular carcinoma ≤3cm exhibited a shorter time to relapse. Recurrence rates were similar, as long as complete response was achieved. ABSTRACT Objective: To describe the radiological characteristics of hepatocellular carcinoma (HCC) lesions that achieved a complete response following drug-eluting bead transarterial chemoembolization (DEB-TACE) preceding liver transplantation. Methods: This […]

ABSTRACT Transarterial radioembolization (TARE) with yttrium-90 microspheres is a palliative locoregional treatment, minimally invasive for liver tumors. The neoadjuvant aim of this treatment is still controversial, however, selected cases with lesions initially considered unresectable have been enframed as candidates for curative therapy after hepatic transarterial radioembolization. We report three cases in which the hepatic transarterial radioembolization was used as neoadjuvant therapy in an effective way, allowing posterior potentially curative therapies.

Primary hepatic carcinoid tumors are extremely rare neoplasms derived from hormone-producing neuroendocrine cells. It is difficult to make their diagnosis before biopsy, surgical resection or necropsy. A recent publication described only 94 cases of these tumors. There is no sex predilection and apparently it has no association with cirrhosis or preexisting hepatic disease. The most effective treatment is hepatectomy, and resection is determined by size and location of the lesions.